Kawanabe Takeshi, Kawakami Tamihiro, Yatomi Yutaka, Shimada Shinji, Soma Yoshinao
Department of Dermatology, St. Marianna University School of Medicine, Japan.
J Dermatol Sci. 2007 Oct;48(1):53-60. doi: 10.1016/j.jdermsci.2007.06.002. Epub 2007 Jul 20.
Blood platelets store sphingosine 1-phosphate (S1P) abundantly and release this bioactive lipid extracellularly. S1P acts as an intercellular mediator through interaction with the endothelial differentiation gene (EDG)/S1P family of G protein-coupled receptors. Of the EDG family S1P receptors, EDG-5 (S1P2) is inhibited in migration induced by S1P. Diabetes impairs numerous aspects of tissue repair. Failure of wound angiogenesis is known to delay diabetic wound healing.
We examined whether S1P subcutaneous injection could improve the healing of full-thickness skin wounds in healthy and diabetic mice. We further determine if the combined S1P and EDG-5 (S1P2) antagonist injection in diabetic mice could affect wound healing. Finally, we examined the histopathological findings of the wound following S1P injection in diabetic mice.
Eight- to 10-week-old BALA/c mice, diabetic db/db mice and Wister rats were used for the studies. A full-thickness wound was made on the dorsal skin of the healthy and diabetic mice. Either 10 microM or 100 microM of S1P or vehicle control (BSA/PBS) was injected into the wound bed every day. We calculated the wound area after each injection. EDG-5 (S1P2) antagonist (JTE-013) or vehicle (DMSO) was then injected in addition to the S1P around the dorsal wound of diabetic mice and the wound diameter was measured. Wound tissue samples were excised following injection for histopathological examination.
Wound area in normal BALA/c mice did not significantly decrease upon S1P injection compared to S1P-untreated controls. S1P injection alone showed significant promotion of wound healing in diabetic mice compared to no S1P treatment. The combination of S1P and EDG-5 (S1P2) receptor antagonist administration induced maximal wound healing in diabetic mice. Histopathological examination revealed that S1P induces neo-vascularization potential in rats and diabetic mice wound.
S1P injection in diabetic mice significantly accelerated cutaneous wound healing in the neo-vascularization process. The results demonstrate that S1P affects and sustains all key cellular processes responsible for wound repair and point to a unique potential for this molecule in the therapy of diabetic wounds, particularly as an angiogenic agent in treatment of diabetic wounds.
血小板大量储存鞘氨醇-1-磷酸(S1P)并将这种生物活性脂质释放到细胞外。S1P通过与G蛋白偶联受体的内皮分化基因(EDG)/S1P家族相互作用,作为一种细胞间介质发挥作用。在EDG家族的S1P受体中,EDG-5(S1P2)在S1P诱导的迁移中受到抑制。糖尿病会损害组织修复的多个方面。已知伤口血管生成失败会延迟糖尿病伤口愈合。
我们研究了皮下注射S1P是否能改善健康和糖尿病小鼠全层皮肤伤口的愈合。我们进一步确定在糖尿病小鼠中联合注射S1P和EDG-5(S1P2)拮抗剂是否会影响伤口愈合。最后,我们检查了糖尿病小鼠注射S1P后伤口的组织病理学结果。
使用8至10周龄的BALB/c小鼠、糖尿病db/db小鼠和Wistar大鼠进行研究。在健康和糖尿病小鼠的背部皮肤制造全层伤口。每天向伤口床注射10微摩尔或100微摩尔的S1P或溶剂对照(牛血清白蛋白/磷酸盐缓冲液)。每次注射后计算伤口面积。然后在糖尿病小鼠背部伤口周围除注射S1P外,还注射EDG-5(S1P2)拮抗剂(JTE-013)或溶剂(二甲基亚砜),并测量伤口直径。注射后切除伤口组织样本进行组织病理学检查。
与未注射S1P的对照相比,正常BALB/c小鼠注射S1P后伤口面积没有显著减小。与未进行S1P治疗相比,单独注射S1P在糖尿病小鼠中显示出显著促进伤口愈合的作用。联合给予S1P和EDG-5(S1P2)受体拮抗剂可使糖尿病小鼠伤口愈合达到最大程度。组织病理学检查显示,S1P可诱导大鼠和糖尿病小鼠伤口的新生血管形成潜能。
糖尿病小鼠注射S1P可在新生血管形成过程中显著加速皮肤伤口愈合。结果表明,S1P影响并维持负责伤口修复的所有关键细胞过程,并指出该分子在糖尿病伤口治疗中具有独特的潜力,特别是作为治疗糖尿病伤口的血管生成剂。